Drug Persistence and Incidence of Active Tuberculosis of Tumor Necrosis Factor Alpha Inhibitors Versus Tocilizumab as the First-Line Biological Treatment in Patients with Rheumatoid Arthritis: A Nationwide Population-Based Retrospective Cohort Analysis.

Rheumatol Ther · 2024 · PMC11265025 · PMID 38769252

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

did not reach statistical significancep = 0.069so close (0.05 < p ≤ 0.1)

Infliximab tended to be more associated with a higher risk of nonpersistence compared with tocilizumab, but it did not reach statistical significance (HR 1.19, 95% CI 0.98–1.45, p = 0.069).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.